Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
1.7.2026 11:00:00 CEST | Business Wire | Press release
Haleon, a consumer health company solely focused on better everyday health, today announces a new five-year collaboration with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global Win as One strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630342896/en/
The new agreement builds on Haleon’s existing use of Microsoft 365 Copilot and further supports the wider adoption of AI-powered tools across the business, helping teams automate routine tasks, collaborate more effectively and focus on higher-value work. Importantly, it will also further strengthen Haleon’s digital and AI-enabled infrastructure through further adoption of Microsoft’s agentic AI, security and identity capabilities, helping the company to scale AI securely and responsibly.
Haleon and Microsoft will co-create high-impact AI use cases which deliver value across multiple critical functions, from consumer insights and innovation to supply chain and commercial execution. This will ultimately enable Haleon to deliver better everyday health to consumers globally, for example, through faster scientific research and clinical content development, enhanced marketing content creation and personalisation, and improved forecasting and decision-making across the business.
By harnessing advanced AI capabilities, Haleon will gain deeper insights into evolving consumer needs, drive product innovation at pace, and streamline operations from supply chain through to commercial execution. This will enable Haleon to meet rising consumer demand more quickly, offer personalised health products, and ensure its trusted, science-backed brands are available in the right place, at the right time, to millions more people globally. In turn, this will support Haleon’s global ambitions of reaching one billion more consumers by 2030 and delivering industry-leading shareholder returns.
Claire Dickson, Chief Digital and Technology Officer, Haleon, said: “This collaboration marks a major step forward in how we use digital, data and AI to deliver our global strategy - driving growth, improving productivity and building a more agile, performance-focused culture. We’re already embedding AI capabilities across the business, delivering measurable results and efficiencies in areas including consumer insights, marketing, R&D and supply chain. By combining Microsoft’s cloud and AI capabilities with Haleon’s deep consumer health expertise, we’re accelerating our AI progress — simplifying how we work, unlocking more value from our data, accelerating innovation and helping our teams make faster, smarter decisions to benefit our consumers.”
Darren Hardman, CEO, Microsoft UK & Ireland, said: “Haleon is moving with real pace and purpose on its AI journey, using Microsoft cloud and AI capabilities to turn ambition into impact across the entire organisation. From consumer insights and marketing to R&D, supply chain and decision-making, Haleon is already showing how AI can help teams work smarter, innovate faster and deliver meaningful benefits for consumers. We’re proud to support Haleon as it scales AI securely and responsibly, helping the company unlock more value from its data and accelerate its mission to deliver better everyday health to millions more people around the world.”
By using Microsoft Azure as its core cloud platform and Microsoft Copilot as part of its enterprise AI foundations, Haleon will benefit from scalable infrastructure, advanced analytics and Microsoft’s enterprise-grade security capabilities. This includes strengthened identity, governance and threat protection to help safeguard data, systems and AI-powered workflows as Haleon deploys AI responsibly, safely and at scale.
The agreement supports Haleon’s ambition to build an AI-powered, decision-intelligent enterprise, where data and insights flow seamlessly to enable faster, smarter, more consumer-centric decisions. This includes advancing next-generation agentic AI capabilities, to allow Haleon’s digital and technology teams to manage, govern and secure intelligent digital agents. These agents will work alongside Haleon’s teams to help them spot opportunities earlier, respond more quickly, and deliver better outcomes for consumers, customers and health professionals.
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world. For more information, please visit www.haleon.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260630342896/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion1.7.2026 13:19:00 CEST | Press release
Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quality at lower cost, companies stay focused on serving customers rather than defending position, and society is better off for it. This ruling supports a healthier, more competitive market for the way people compare products and services — and that is good for everyone who shops," said Dan Greaves, Head of Communications and Policy, Klarna. Klarna acquired PriceRunner in 2022 to add rich product discovery, price comparisons, and product reviews to the Klarna app, and drive high-intent traffic to retail partners. Klarna has si
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 13:10:00 CEST | Press release
The acquisition consolidates its pan-European footprint, by expanding in Switzerland and Liechtenstein, as well as creating opportunities to expand in other international wealth centres. The investment enhances Objectway’s core-to-digital banking capabilities and strengthens its end-to-end offering for private banks and their cross-border wealth business.Key takeaways Objectway strengthens its positioning in Switzerland and in key international cross-border wealth management hubs. The acquisition enhances Objectway’s end-to-end private banking proposition for mid-sized to large institutions, leveraging core banking expertise and scalable digital solutions. Objectway extends international operational footprint across Switzerland, Singapore and Tunisia, accelerating its growth strategy and reinforcing its ability to support banks facing cross-border expansion, consolidation, regulatory pressure and increasing operational complexity. Objectway, a global wealthtech partner for banking, wea
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 13:00:00 CEST | Press release
Belgium’s only company selected in the latest EIC Accelerator funding round.Up to €7.5 million in blended finance: a €2.5 million non-dilutive grant plus a planned €5 million EIC Fund equity investment.Funding advances Azalea’s smart contact lens platform from technical validation into the clinic.Selection provides independent validation of Azalea Vision’s technology, clinical strategy and commercial potential. Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features
Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 12:34:00 CEST | Press release
ChIQ™ becomes the second FDA-approved product from Croma's saypha® portfolio in the U.S., expanding treatment options for facial volume restoration. Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom